News search

    E.g., 23/11/2024
    E.g., 23/11/2024
    Cardiovascular risk factors (particularly metabolic syndrome, insulin resistance, and diabetes) alter coronary microvascular function and increase the risk of atherosclerotic disease, which itself leads to changes in the coronary microcirculation.
    Research
    19 Sep 2024
    JACC: Cardiovascular Imaging: Cardiometabolic risk factors in apparently healthy individuals are linked to altered coronary microcirculation

    A study from CNIC reveals how risk factors and subclinical atherosclerosis affect heart microcirculation in asymptomatic middle-aged individuals. The research, published in JACC: Cardiovascular Imaging, highlights the importance of assessing the heart vessels' ability to regulate blood flow and predict future cardiovascular risk
    Figure
    Research
    13 Sep 2024
    The RESILIENCE trial: preventing heart injury caused by anticancer drugs

    RESILIENCE is a clinical trial funded by the European Commission (H2020 Programme) that aims to reduce the prevalence of heart failure in cancer survivors
    About the CNIC
    12 Sep 2024
    Join CNIC through CURE HEART AND BRAIN (COFUND)
    CNIC researchers
    Research
    30 Aug 2024
    Nature Medicine: CNIC scientists discover a new cardiovascular risk factor and identify a drug able to reduce its effects

    Two studies carried out at the CNIC provide key information about a newly identified cardiovascular risk factor, clonal hematopoiesis, and its treatment with the ancient medication colchicine
    Dr. Fuster recibe el premio
    About the CNIC
    27 May 2024
    Dr Valentín Fuster receives the prestigious Lifetime Achievement Award of the World Heart Federation (WHF
    María Jesús Andrés, Carla Espinós (detrás), Rosa M Nevado (delante, al lado de MJA), Miguel de la Fuente, Rosa Carmona, Ana Barettino, Vicente Andrés, Pilar Gonzalo e Ignacio Benedicto.
    Research
    19 Apr 2024
    PNAS: CNIC scientists identify the key cell type for strategies to prevent atherosclerosis in progeria syndrome

    The elimination of progerin from vascular smooth muscle cells, but not from endothelial cells, prevents the atherosclerosis associated with Hutchinson-Gilford progeria syndrome (HGPS)
    Agustín Clemente-Moragón, Borja Ibáñez, Anabel Díaz-Guerra, Laura Cádiz, Carlos Galán-Arriola, Miguel Fernández-Tocino, Mónica Gómez, Rocío Villena-Gutiérrez, y Eduardo Oliver.
    Research
    16 Apr 2024
    JACC: CardioOncology: CNIC scientists identify therapeutic targets for the prevention of heart injury linked to cancer treatment

    The study, published in the journal JACC: CardioOncology, identifies mitochondrial function and heart metabolism as targets for possible treatments to protect against anthracycline-induced cardiotoxicity
    Carlos Torroja, Jacob F. Bentzon, Paula Nogales, Laura Carramolino, Vanessa Cumbicus, Daniel Morales, Ana Dopazo, Verónica Labrador y Alberto Benguria
    Research
    1 Feb 2024
    Nature Cardiovascular Research: New approach to the design of therapies that enhance the effect of cholesterol-lowering drugs

    A study published in Nature Cardiovascular Research reveals smooth muscle-derived cells as a new target for reducing the size of atherosclerotic plaque. The results open up new avenues for the design of treatments to enhance the beneficial effect of cholesterol-lowering drugs
    Ayelén M. Santamans y Guadalupe Sabio
    Research
    19 Jan 2024
    Science Advances: First therapeutic target for preserving heart function in patients with pulmonary hypertension

    A team led by scientists from the CNIC and CNIO has identified a potential therapeutic target that protects the heart in patients with pulmonary hypertension
    Edward Pearce
    Research
    21 Dec 2023
    Edward Pearce: "Prevention is always more economical than treating a heart attack or a heart transplant"

    Johns Hopkins UniversityBloomberg School of Public HealthBaltimore